To investigate the oncological outcome of nonagenarians with bladder cancer, as a substantial rise in bladder cancer in the old-old age group in the upcoming decades is expected, due to demographic changes and the peak incidence around the age of 85 years. The paucity of data of nonagenarians prompted us to investigate the outcomes of such patients.
Introduction
Bladder cancer is the most common malignancy involving the urinary system and the ninth most common malignancy worldwide [1] , with 118 000 annual new cases and 52 000 deaths per year in Europe [2] . Age is an independent risk factor for bladder cancer thus making it primarily a disease of the elderly, commonly occurring beyond the 70th year of life [3] . Data from the California Cancer Registry show a peak incidence of bladder cancer in the 85-95 years age group [4] .
Due to demographic changes and increase in life-expectancy, the fastest growing population-segment is the age group of ≥85 years. Therefore a substantial increase in elderly patients with bladder cancer can be expected [5, 6] .
Age and comorbidities are important factors influencing treatment strategy and outcome of patients with bladder cancer. The American Society of Anesthesiologists Physical Status Classification (ASA-score) is, for instance, a predictor of mortality after radical cystectomy (RC) [7] . Several publications report on the oncological outcome of octogenarians with bladder cancer and the feasibility of RC in octogenarians, with an acceptable rate of major complications and mortality [8] [9] [10] [11] .
To date no study is available that has specifically addressed bladder cancer in nonagenarians. The aim of this multicentric study was therefore to analyse the management, recurrence, and outcome of a consecutive series of nonagenarians with newly diagnosed or recurrent bladder cancer.
Patients and Methods
A retrospective multicentre analysis of patients aged ≥90 years with recurrent or newly diagnosed bladder cancer was performed between January 2006 and December 2017. Data were collected from seven Austrian and one Italian urological institution.
Clinical parameters were generated via a retrospective chart review including assessment of age, gender, ASA-score, pathological staging (TNM classification system of the Union Internationale Contre le Cancer [12] ), cancer recurrence, tumour management, and overall (OS) and cancer-specific survival (CSS).
All data are presented as median and interquartile range (IQR). All analyses were performed using the Statistical Package for the Social Sciences (SPSS â ) Statistics for Windows, version 20.0 (SPSS Inc., IBM Corp., Armonk, NY, USA). Chi-squared and the non-parametric Kruskal-Wallis tests were used to analyse differences in baseline and pathological characteristics. Kaplan-Meier plots were applied for estimating the OS and CSS, and statistical significances were analysed with the log-rank test. A P < 0.05 was considered to indicate statistical significance.
Results

Patient Characteristics
A total of 123 patients [87 men, 36 women; median (range) age 91 (90-99) years] were eligible for this analysis ( Table 1) . The male to female ratio was 2.4:1. The median (range) follow-up was 8 (1-132) months. The ASA-score was as follows: II, 38%; III, 50%; IV, 12% (Table 1) .
Histology and Management
In all, 70 patients (57%) had a de novo diagnosis and 53 patients (43%) a recurrent tumour. Histology revealed pTa tumour in 48 patients (39%), a pT1 tumour in 35 patients (28%), and in 40 patients (33%) a muscle invasive ≥pT2 disease ( Table 1 ). The rate of high-grade tumours was 67% (n = 82). All cases of low-grade tumours were histologically pTa (n = 41), and seven pTa tumours (15%) were classified as high grade.
In those with a de novo diagnosis, 34% (n = 28) had a pTa, 28% (n = 23) a pT1, and 39% (n = 32) a >pT2 tumour; in patients with recurrent bladder cancer, the respective figures were: 50% (n = 20), 30% (n = 12), and 20% (n = 8), respectively. Adjuvant therapies were rarely used: BCG in 13 cases; one patient received adjuvant chemotherapy, and nobody had radiotherapy.
A total of 83 (67.5%) patients remained recurrence free, 31 patients (25.2%) developed one recurrence, and nine patients (7.3%) two or more recurrences. In patients with a pTa tumour (n = 48) cancer recurred in 20 (42%), with an upstaging to pT1 in eight. In patients with pT1 tumours (n = 35) cancer recurred in 12 (34%), with pTa in four, pT1 in five, ≥pT2 in two and cancer in situ (CIS) in one patient. A total of 12.5% (n = 5) patients with muscle-invasive bladder cancer underwent a second transurethral resection of the bladder (TURB) and 7.5% (n = 3) had a third resection. RC was performed in nine patients (7%) with ureterocutaneostomy as the urinary diversion in all. 
Outcome
The median OS was 16.0 months ( Table 2 ). The median (95% CI) OS for the men was 16.0 (10.4-21.6) months and 22.0 (8.0-36.0) months for the women (P = 0.6) (Fig. 1 ). For patients with pTa tumours the median OS was 30.0 months, with no difference between pTa high-grade or pTa low-grade tumours, vs 14.0 months for pT1, and 6.0 months for ≥pT2 tumours (P = 0.009) ( Table 2 ; Fig. 2 ). A total of 67 patients (59%) died during follow-up. The overall mortality rate of patients with pTa tumours was 40%, with pT1 tumours 60%, and with ≥pT2 tumours 75%. Bladder cancer, as the definite cause of death, was reported in 11 cases (all ≥pT2), with a median (95% CI) CSS of 10 (5.0-14.9) months.
The median (95% CI) OS of the nine patients in our series that underwent RC was only 5 (2.1-7.9) months. The OS was ≤3 months in three patients and between 4 and 12 months in three patients. The remaining three patients survived for >12 months, i.e. 38, 71 and 72 months, respectively.
Patients with ≥pT2 tumours that did not receive RC had a median (95% CI) OS of 7 (3.4-10.6) months.
The ASA-score had a profound influence on OS (Table 2 ; Figs 3,4) . Patients with an ASA-score of II had a median OS of 30 months vs 12.0 months in the ASA-score III group, and only 4.0 months with an ASA-score of IV (P = 0.11). Also, after stratification by tumour-stage the ASA-score was strongly associated with OS (Table 2 ; Fig. 4 ).
There were no significant differences in tumour stage between the ASA-score groups (P = 0.34). The ASA-score distribution in the small RC series was: II, five; III, three; and IV, one. The median OS in these three ASA-score subgroups was: II, 24 months; III, 4 months; IV, 3 months. 
Discussion
Bladder cancer is mainly a disease of the elderly, with an incidence peak between the eighth and tenth life decade [4] . Demographic changes will lead to a significant increase in bladder cancer, causing a substantial public health challenge in the future [13] . Age is a major determinant when managing elderly patients with invasive bladder cancer.
To our knowledge this is the first study describing management and outcome selectively of nonagenarians with bladder cancer. The major limitation of our present study is its retrospective nature with non-uniform management strategies by the participating institutions. Furthermore, data on quality of life and detailed assessment of comorbidities (e.g. Charlson Co-morbidity Index) are lacking. Despite these shortcomings, the data generated provide some guidance for the management of this challenging and ever-increasing cohort.
The major clinical factors in managing old-old patients with bladder tumours are chronological age, comorbidities, and tumour stage. In our present series OS was strongly correlated to the ASA-score and tumour stage (Table 2; Figs 2,3). Table 2 shows that the three groups of patients in this series (pT1 and ASA-score IV; >pT2 ASA-score III or ASA-score IV) have a median survival of <10 months. In these three cohorts any management should be primarily palliative, aiming to minimise hospitalisation and ensuring an adequate quality of the remaining life span. In our opinion, guideline management recommended in these stages such as secondary TURB, BCG therapy or RC is seldom indicated.
Nonagenarians with an invasive bladder tumour and an ASAscore of II deserve a more aggressive treatment, as 50% of patients survive for >2 years. In our present series, nine patients underwent RC with a median OS of 5 months, yet one-third survived for >2 years. Due to the retrospective nature of our present study is was difficult to reliably assess the indication for RC in these nine patients, yet in most cases it was imperative mainly due to recurrent bleeding that could not be otherwise managed.
Several reports on RC in octogenarians with muscle-invasive bladder cancer are available, with acceptable mortality and morbidity, and similar CSS compared to younger patients [8, 9, 14] . However, the 90-day mortality after RC increases with age with up to 20-30% in octogenarians, compared to 4.7% in patients in their sixties [15, 16] .
In patients with a pTa tumour, OS was also correlated to the ASA-score, yet was >24 months in all three ASA-score groups (Table 2) . Given the 42% recurrence rate of pTa tumours in our present series, we suggest that management should be the same as that offered to younger patients, i.e. secondary TURB, close follow-up and, possibly, also adjuvant therapy. The same holds true for pT1 patients and an ASAscore of II/III. Although age does not seem to affect the initial response to BCG therapy, the administration of maintenance BCG therapy in patients aged >80 years should be avoided due to increased complications compared to younger patients [17] .
Conclusions
In nonagenarians with bladder cancer, pTa/pT1 and >pT1 tumour stages are nearly equally distributed. About twothirds of patients develop no recurrence after initial TURB. OS is 16 months and strongly associated to ASA-score and tumour stage. As shown in Table 2 , management should be directed considering these two parameters, as it allows identification of sub-cohorts with a poor survival probability in whom primarily palliative care is indicated. 
